Syngene

Founded in 1993, Syngene International operates from Bangalore, India, offering comprehensive services in drug development. The company has not reported any significant pivots in its strategy or operations. In July 2023, Syngene International, a portfolio company of CDPQ, GIC, Abu Dhabi Investment Authority, Goldman Sachs AIMS Group, Monetary Authority of Singapore and Morgan Stanley Alternative Investment Partners, agreed to acquire Stelis Biopharma’s manufacturing unit from Stelis Biopharma Private Limited for INR 6. 17 billion.

Syngene International Limited specializes in providing comprehensive contract research, development, and manufacturing services tailored to the biopharma and pharmaceutical industries. Its primary offerings include integrated drug discovery and development solutions for large and small molecules. The company operates through its innovative platform, SynVent, which facilitates therapeutic discovery and aids clients in navigating complex disease areas. Syngene serves a global client base that includes leading pharmaceutical and biotech companies, particularly in North America, Europe, and Asia, addressing needs in therapeutic development, clinical trials, and commercialization support.